BlinkLab Secures Funding for Diagnostic Expansion

BlinkLab Limited (ASX:BB1) has successfully raised AU$17.5 million through an oversubscribed share placement to institutional and sophisticated investors at AU$0.65 per share. The funds will support the ongoing FDA trial for BlinkLab Dx1, a smartphone-based diagnostic tool for autism, and its regulatory approval in Europe. Additionally, the company aims to expand into ADHD diagnostics with BlinkLab Dx2, using similar technology. The capital raise will enable BlinkLab to enhance its platform development, extend its patent portfolio, and prepare for U.S. commercialization. CEO Dr. Henk-Jan Boele highlighted the importance of this funding for advancing BlinkLab’s growth, while Chairman Brian Leedman emphasized strategic investor alignment for future expansion. The company is strategically placed to tackle the substantial gap in diagnosing neurodevelopmental disorders by offering AI-driven, scalable diagnostic solutions.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au